Premium
Intramuscular picenadol in patients with postoperative pain
Author(s) -
BRUNELLE ROCCO L.,
GOLDSTEIN DAVID J.,
GEORGE RICHARD E.,
ZIMMERMAN DENNIS M.
Publication year - 1993
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1993.tb00375.x
Subject(s) - pethidine , placebo , medicine , anesthesia , analgesic , somnolence , dose , opioid , opioid antagonist , adverse effect , (+) naloxone , alternative medicine , receptor , pathology
1 The analgesic efficacy and safety of a single 50 mg intramuscular dose of rac‐picenadol, a centrally acting agonist‐antagonist opioid analgesic, were compared with pethidine (meperidine) 100 mg and placebo in 60 patients with moderate to severe postoperative pain using hourly pain intensity and relief measurements for up to 6 h following injection of the study medications. 2 Both picenadol and pethidine were statistically significantly ( P < 0.05) more effective than placebo in reducing pain intensity and in increasing total relief. Patients receiving picenadol and pethidine had higher frequency of somnolence than patients receiving placebo. In addition, patients receiving picenadol 50 mg experienced a higher incidence of confusion (30%), speech disorders (30%), and tremors (25%) than the patients receiving either pethidine or placebo. 3 These results were compared with those of a similar study which investigated the effects of a 25 mg intramuscular dose of picenadol vs pethidine and placebo. This comparison suggests that 25 mg of picenadol is a more acceptable dosage since both 25 and 50 mg were effective dosages.